We’re tracking in-house compensation. Take the Law360 Survey
Click here
In re: Xencor, Inc.
-
January 23, 2024
The Federal Circuit has granted the U.S. Patent and Trademark Office's bid to send Xencor Inc.'s application for an antibody patent back for further proceedings to a new administrative appellate panel.
-
December 01, 2023
Xencor is urging the Federal Circuit to reject what it calls the U.S. Patent and Trademark Office's "eleventh hour" effort to terminate an appeal of a Patent Trial and Appeal Board decision, which backed an examiner's denial of a patent application on antibodies that can be used in autoimmune disease treatments.
-
November 28, 2023
The U.S. Patent and Trademark Office says the Federal Circuit should terminate Xencor Inc.'s appeal of a Patent Trial and Appeal Board decision that backed an examiner's denial of an application for a patent on antibodies that can be used in autoimmune disease treatments.
-
October 12, 2023
A U.S. Patent and Trademark Office decision rejecting Xencor Inc.'s application for a patent on antibodies that can be used in autoimmune disease treatments could significantly hinder the ability to obtain antibody patents, legal and medical groups have told the Federal Circuit.